Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.66 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168379 | 0.88 | PTGS2 (0.65) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6168468 | 0.85 | PTGS2 (0.72) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6167000 | 0.83 | PTGS2 (0.57) | PTGS2PTGS1PTGESCYP2C9PDPK1 | |
| SCHEMBL6167128 | 0.82 | PTGS2 (0.73) | PTGS2PTGS1PTGESCYP2C9PDPK1 | |
| SCHEMBL6164242 | 0.81 | PDPK1 (0.66) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6168792 | 0.80 | PTGS2 (0.73) | PTGS2PTGS1PTGESCYP2C9PDPK1 | |
| SCHEMBL3239998 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1PTGESCYP2C9PDPK1 | |
| SCHEMBL6169025 | 0.79 | PTGS2 (0.65) | PTGS2PTGS1PTGESCYP2C9PDPK1 | |
| SCHEMBL6166770 | 0.79 | PTGS2 (0.65) | PTGS2PTGS1PTGESCYP2C9PDPK1 | |
| SCHEMBL4588766 | 0.79 | PTGS2 (0.71) | PTGS2PTGS1PTGESCYP2C9PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233959-B1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PROD INC (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030236258-A1 | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | PFIZER INC. | 2003-12-25 | — | — | US | disclosed |
| US-6531492-B1 | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | PFIZER INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1233959-A1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | Pfizer Products Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001040216-A1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236258-A1 | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | PTGS1, SULT2A1, PTGES3 | PTGS2 4/4885PTGS1 1/4885PTGES 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.